<乌鸦传媒>Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma Studies appear to contradict benefit previously shown with pembrolizumab in this setting Sep 12, 2022
<乌鸦传媒>Colorectal Cancer Burden on the Rise in Developed Countries Global study predicts an uptick in incidence and mortality through 2040 Sep 12, 2022
<乌鸦传媒>Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinib About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists Sep 12, 2022
<乌鸦传媒>'Striking' Colon Cancer Data Spur Mid-Presentation Ovation at ESMO Preoperative immunotherapy combo in dMMR disease yields major pathologic response in 95% Sep 12, 2022
<乌鸦传媒>Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Option More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1 Sep 12, 2022
<乌鸦传媒>Add-On Pembrolizumab Misses in Locally Advanced Head and Neck Cancer Post hoc data point to possible benefit in patients with higher PD-L1 levels Sep 11, 2022
<乌鸦传媒>Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLC Study also shed lights on what may lead to lung cancer in never smokers Sep 11, 2022
<乌鸦传媒>'Potential New Standard' for Progressing Desmoid Tumors Risk of disease progression or death reduced by 71% with oral gamma secretase inhibitor Sep 10, 2022
<乌鸦传媒>Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancer No clinical benefit boost with anti-CD73 oleclumab added to durvalumab and chemo Sep 10, 2022
<乌鸦传媒>Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib Sep 09, 2022
<乌鸦传媒>Worse OS With Rucaparib First in Trial of Recurrent, BRCA+ Ovarian Cancer A closer look at why PARP inhibitor's third-line indication was withdrawn Sep 09, 2022
<乌鸦传媒>Antibody-Drug Conjugate Prolongs Survival in Metastatic Breast Cancer Positive outcome with sacituzumab govitecan leads to questions about ADC sequencing Sep 09, 2022
<乌鸦传媒>Robotic Surgery Tops Laparoscopic Surgery for Middle and Low Rectal Cancer Randomized trial shows fewer positive circumferential resection margins with robotic technique Sep 09, 2022
<乌鸦传媒>CAR-T Therapy Effective in Youngest Kids With ALL Analysis shows safety and outcomes equivalent to those reported in older children Sep 08, 2022
<乌鸦传媒>Study: Microwave Ablation for Lung Nodules Effective as Last Resort Good option for patients who can't have surgery or radiotherapy, surgeon says Sep 08, 2022
<乌鸦传媒>Rezvilutamide Bests Bicalutamide in Metastatic Prostate Cancer Combined with ADT, the androgen-receptor inhibitor significantly improved OS, radiographic PFS Sep 07, 2022
<乌鸦传媒>Coping With a Deadly Prognosis An impossible battle with the rarest of cancers Sep 06, 2022 podcast
<乌鸦传媒>Jane Fonda's Non-Hodgkin Lymphoma The award-winning actress opened up about her latest health news Sep 06, 2022
<乌鸦传媒>Keytruda Plus T-VEC Falls Short in Unresectable Melanoma No significant survival benefit with combination, but certain patients lived longer Sep 02, 2022
<乌鸦传媒>A Light at the End of the Tunnel for Low-Risk Prostate Cancer? The MUSIC model might improve quality of life and prevent overtreatment Sep 02, 2022
<乌鸦传媒>10-Year Follow-Up Confirms Benefit of Chemoradiotherapy in MIBC Patients Findings "supported a change in clinical practice" Sep 01, 2022
<乌鸦传媒>Does PARP Inhibitor Maintenance Induce Platinum Resistance in Ovarian Cancer? Shorter progression-free interval with platinum chemotherapy after olaparib maintenance Sep 01, 2022
<乌鸦传媒>2 Years of Endocrine Therapy, 2 Decades of Protection From Metastatic Breast Cancer Tamoxifen protects low-risk premenopausal patients, goserelin helps high-risk patients Aug 31, 2022
<乌鸦传媒>Trainees May Miss More Sessile Serrated Polyps on Colonoscopy But resident or fellow involvement didn't have a negative impact on other key quality indicators Aug 31, 2022
<乌鸦传媒>Bispecific Antibody Active in Heavily Treated Multiple Myeloma Responses in 60% of patients who had received a median of five prior lines of therapy Aug 30, 2022
<乌鸦传媒>Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancer Lower all-cause, cancer-specific mortality in women who received the drugs around time of surgery Aug 29, 2022
<乌鸦传媒>Pralsetinib Shows Promise in Diverse RET Fusion-Positive Cancers An ORR of 57% supports results previously observed in NSCLC and thyroid cancer Aug 26, 2022
<乌鸦传媒>Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes Overall response rates were 67% with decitabine, 48% with azacitidine Aug 22, 2022
<乌鸦传媒>Intensive Endoscopy Might Not Be One-and-Done for Gastric Cancer Surveillance High-risk group had similar new lesion detection rates initially and at 15 months Aug 22, 2022
<乌鸦传媒>Florida Oncologist Presumed Lost at Sea The Coast Guard recently suspended its search for Chaundre Cross, MD, of Naples Aug 19, 2022
<乌鸦传媒>PK Modulator Shows Promise in Thalassemia In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients Aug 17, 2022
<乌鸦传媒>Patients With Head/Neck Cancer See Lower Stroke Risk With Initial Surgery Enough reason to prefer the scalpel to definitive radiotherapy? Aug 12, 2022
<乌鸦传媒>Epstein-Barr Virus Linked With Gastric Cancer Meta-analysis shows a 7.5% prevalence across 37 countries Aug 12, 2022
<乌鸦传媒>'Clinically Meaningful' Improvement in SCLC Patients With Pembrolizumab/Chemo Combo Long-term follow-up shows continued survival benefit as first-line treatment Aug 11, 2022
<乌鸦传媒>Study Confirms Big Drop in Power Morcellator Use, Shows Lag in Containment Systems But whether containment bags really work remains open to question, authors say Aug 11, 2022
<乌鸦传媒>Mandy Moore's Immune Thrombocytopenic Purpura What does it mean for the pregnant pop singer/actress? Aug 10, 2022
<乌鸦传媒>Triple Therapy Continues to Impress in Metastatic NSCLC With High-Risk Mutations Meaningful survival boosts in POSEIDON trial of front-line durvalumab, tremelimumab, and chemo Aug 10, 2022
<乌鸦传媒>Survey: 77% of Women With Lung Cancer Report Sexual Dysfunction Results show need to integrate sexual health into care, researcher says Aug 09, 2022
<乌鸦传媒>Neodjuvant Chemoimmunotherapy Takes Another Step Forward in Stage IIIA-B NSCLC Phase II trial supports neoadjuvant nivolumab plus chemotherapy Aug 09, 2022
<乌鸦传媒>New Data Bolster Atezolizumab as Adjuvant Tx in NSCLC Overall survival benefit now demonstrated Aug 09, 2022
